These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 29032452)

  • 1. Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect.
    Rezk MF; Pieper B
    Rheumatol Ther; 2017 Dec; 4(2):209-218. PubMed ID: 29032452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Clinical Implications of Nocebo Effects for Biosimilar Therapy.
    Colloca L; Panaccione R; Murphy TK
    Front Pharmacol; 2019; 10():1372. PubMed ID: 31849647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars.
    Rezk MF; Pieper B
    Adv Ther; 2018 Jun; 35(6):749-753. PubMed ID: 29873005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
    Kim H; Alten R; Avedano L; Dignass A; Gomollón F; Greveson K; Halfvarson J; Irving PM; Jahnsen J; Lakatos PL; Lee J; Makri S; Parker B; Peyrin-Biroulet L; Schreiber S; Simoens S; Westhovens R; Danese S; Jeong JH
    Drugs; 2020 Feb; 80(2):99-113. PubMed ID: 32002851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
    Solitano V; D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
    Expert Rev Clin Immunol; 2020 Oct; 16(10):1019-1028. PubMed ID: 32954893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?
    D'Amico F; Solitano V; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2021 Jan; 21(1):47-55. PubMed ID: 32857634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nocebo effect: a clinical challenge in the era of biosimilars.
    Pouillon L; Socha M; Demore B; Thilly N; Abitbol V; Danese S; Peyrin-Biroulet L
    Expert Rev Clin Immunol; 2018 Sep; 14(9):739-749. PubMed ID: 30118338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars: From Production to Patient.
    Sheridan M; Massich M; Ashourian N
    J Infus Nurs; 2024 Jan-Feb 01; 47(1):19-29. PubMed ID: 38211611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A place for biosimilars in the changing multiple sclerosis treatment landscape.
    Greenberg B; Giovannoni G
    Mult Scler Relat Disord; 2023 Sep; 77():104841. PubMed ID: 37467536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.
    Carrascosa JM; Jacobs I; Petersel D; Strohal R
    Dermatol Ther (Heidelb); 2018 Jun; 8(2):173-194. PubMed ID: 29549597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
    Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
    Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients.
    Pouillon L; Danese S; Hart A; Fiorino G; Argollo M; Selmi C; Carlo-Stella C; Loeuille D; Costanzo A; Lopez A; Vegni E; Radice S; Gilardi D; Socha M; Fazio M; González-Lorenzo M; Bonovas S; Magro F; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2019 May; 49(9):1181-1187. PubMed ID: 30932219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies.
    Odinet JS; Day CE; Cruz JL; Heindel GA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):952-959. PubMed ID: 30247100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent.
    Kristensen LE; Alten R; Puig L; Philipp S; Kvien TK; Mangues MA; van den Hoogen F; Pavelka K; Vulto AG
    BioDrugs; 2018 Oct; 32(5):397-404. PubMed ID: 30269270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey.
    Frantzen L; Cohen JD; Tropé S; Beck M; Munos A; Sittler MA; Diebolt R; Metzler I; Sordet C
    Joint Bone Spine; 2019 Jul; 86(4):491-496. PubMed ID: 30659920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects.
    Smolen JS; Caporali R; Doerner T; Fautrel B; Benedetti F; Pieper B; Jang M
    RMD Open; 2021 Jun; 7(2):. PubMed ID: 34099538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars Have Arrived: Rituximab.
    Greenwald M; Tesser J; Sewell KL
    Arthritis; 2018; 2018():3762864. PubMed ID: 29765782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars in IBD: What Every Clinician Needs to Know.
    Angyal A; Bhat S
    Curr Gastroenterol Rep; 2024 Mar; 26(3):77-85. PubMed ID: 38243154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?
    Baumgart DC; Misery L; Naeyaert S; Taylor PC
    Front Pharmacol; 2019; 10():279. PubMed ID: 30983996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.